Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma.

Kato, Harumi; Yamamoto, Kazuhito; Higuchi, Yusuke; Yamamoto, Hideyuki; Saito, Toko; Taji, Hirofumi; Yatabe, Yasushi; Nakamura, Shigeo; Kinoshita, Tomohiro

Kato, Harumi; Yamamoto, Kazuhito; Higuchi, Yusuke; Yamamoto, Hideyuki; Saito, Toko; Taji, Hirofumi; Yatabe, Yasushi; Nakamura, Shigeo; Kinoshita, Tomohiro.

Affiliation

Kato H; Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.

Chemotherapy ; 62(1): 19-22, 2017.

Article in En | MEDLINE | ID: mdl-27226129

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antibodies, Monoclonal/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cisplatin/administration & dosage; Deoxycytidine/analogs & derivatives; Dexamethasone/administration & dosage; Lymphoma, T-Cell/drug therapy; Aged; Deoxycytidine/administration & dosage; Female; Humans; Lymphadenopathy/diagnosis; Lymphatic Metastasis; Lymphoma, T-Cell/pathology; Receptors, CCR4/immunology; Salvage Therapy; Tomography, X-Ray Computed; Gemcitabine

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell / Cisplatin / Deoxycytidine / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal Type of study: Diagnostic_studies Limits: Aged / Female / Humans Language: En Journal: Chemotherapy Year: 2017 Type: Article Affiliation country: Japan

Search on Google

XML

PubMed Links